Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 2 Interventional

Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

ClinicalTrials.gov ID: NCT07096778

Public ClinicalTrials.gov record NCT07096778. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Open-Label, Multicenter Study of Inobrodib in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to learn more about the anti-cancer activity of inobrodib, when given in combination with pomalidomide and dexamethasone, in patients with multiple myeloma that has come back following treatment and which no longer responds to available therapies. The study treatment will not be compared to any other treatment and patients will know what treatment they are receiving. This study will also further explore the side effects of inobrodib in combination with these other medicines.

Study identification

NCT ID
NCT07096778
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
CellCentric Ltd.
Industry
Enrollment
100 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 21, 2026
Primary completion
Nov 30, 2029
Completion
Nov 30, 2029
Last update posted
Jul 29, 2026

2026 – 2029

United States locations

U.S. sites
20
U.S. states
17
U.S. cities
20
Facility City State ZIP Site status
Mayo Clinic Arizona Phoenix Arizona 85054 Recruiting
University of California, San Francisco San Francisco California 94143 Recruiting
Mayo Clinic Florida Jacksonville Florida 32224 Recruiting
H Lee Moffitt Cancer Center & Research Institute Tampa Florida 33612 Recruiting
Winship Cancer Institute Atlanta Georgia 30322 Recruiting
University of Chicago Medical Center Chicago Illinois 60637 Recruiting
American Oncology Partners, PA Bethesda Maryland 20817 Recruiting
Dana-Farber Cancer Institute Boston Massachusetts 02215 Recruiting
University of Michigan Ann Arbor Michigan 48109 Recruiting
Mayo Clinic Rochester Minnesota 55905 Recruiting
Washington University School of Medicine St Louis Missouri 63110 Recruiting
University of Nebraska Medical Center Omaha Nebraska 68198 Recruiting
John Theurer Cancer Center at Hackensack University Medical Center Hackensack New Jersey 07601 Recruiting
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey 08901 Recruiting
Levine Cancer Institute Charlotte North Carolina 28204 Recruiting
Wake Forest University Health Sciences Winston-Salem North Carolina 27157 Recruiting
Cleveland Clinic Cleveland Ohio 44195 Recruiting
University of Pennsylvania, Abramson Cancer Center Philadelphia Pennsylvania 19104 Recruiting
Fred Hutchinson Cancer Center Seattle Washington 98109 Recruiting
Froedtert Hospital & the Medical College of Wisconsin Milwaukee Wisconsin 53226 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07096778, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 29, 2026 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07096778 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →